Heather Wakelee, of Stanford University Medical Center, discusses the importance of molecular profiling in predicting the response of EGFR inhibitors for patients with non-small cell lung cancer.
Heather Wakelee, from Stanford University Medical Center, discusses the importance of molecular profiling in predicting the response of EGFR inhibitors for patients with non-small cell lung cancer (NSCLC).
Molecular profiling is a necessary step beyond the initial diagnosis of NSCLC, Wakelee explains. EGFR mutations are found in about 10 percent of patients, but is often higher in subpopulations.
Current trials are comparing targeted therapies to chemotherapy. Patients are demonstrating better responses and longer progression rates by starting with the appropriate targeted therapy, Wakelee says, if the EGFR or ALK mutation is present.
Traditional Definition of ‘High-Risk’ in Patients With CLL and SLL Outdated, Needs to be Revisited
December 7th 2020In an interview with CURE®, Dr. Jan A. Burger discusses how the results of two phase 3 studies could help redefine what constitutes as low or high risk in patients with CLL or SLL.
Read More
To gain a better understanding of the issues faced by geriatric patients with cancer, and to determine how much of a role nutrition plays in outcomes, Dr. Grant Williams, a geriatrician oncologist and assistant professor at the University of Alabama, Birmingham, worked with colleagues to create a patient-reported assessment tool that bridges the knowledge gap in this patient population.
Read More